Ann: AGM Chairman's Address and Investor Presentation, page-6

Candour explained that the market didn't understand the gravity of what Promarker D will provide to the health industry of America, and it should become the standard of care for ALL diabetic patients, especially those who have advanced diabetic kidney disease as they may requite multiple tests per year, which is obviously profound for the company going forward. The other information, which all who have knowledge about Proteomics, was just reiterating the expected revenues. If they can sell 1000000 tests per year the expected revenue will be north of $60,000,000 Au, and they advised that each can do their own calculations of valuation. That should be the company's goal after the first year, I would think, with scope to greatly increase this with new markets opening up across Europe and Asia.